Fratricide-resistant CD7 CAR-T therapy by NUS proves effective in treating relapsed or refractory T-cell leukaemia ...

Analyzing the genetics of patients that responded well to checkpoint blockade revealed mutations in the gene Asxl1 in immune T cells. Disrupting the Asxl1 gene in T cells enhanced response to immune ...

In the clinical battle against leukemia, recent breakthroughs in chimeric antigen receptor T cells (CAR T) have given ...

New research from St. Jude Children's Research Hospital and colleagues found that disrupting Asxl1, a gene in T cells, ...

Tim Hunt, CEO of the Alliance for Regenerative Medicine, said Monday at the 2024 Cell & Gene Meeting on the Mesa that ...

An Iowa State University plant biologist received a $1.8 million federal grant to study a gene that affects both how plants ...

New York Governor Kathy Hochul has considered a statewide ban on smart devices in schools, but many parents, students, and ...

Large pharmaceutical companies were out in force at this week’s 2024 Cell & Gene Meeting on the Mesa, as they look to expand ...

Imagine a world where your own immune cells are transformed into cancer-fighting superheroes. This is the promise of CAR-T ...

Matica Biotechnology, a leading Texas-based viral vector Contract Development and Manufacturing Organization (CDMO), has ...

Blood cancer is one of the most dangerous in the world, but advancements in treatment are changing to landscape for patients.

A new cell therapy, targeting CD7 in leukemia cells, gives a potentially effective treatment for patients with T-cell acute ...